Subcutaneous adipose tissue dopamine D2 receptor is increased in prediabetes and T2D

Purpose To evaluate the dopaminergic signaling in human adipose tissue in the context of obesity and type 2 diabetes (T2D) and potential direct implications in adipose tissue metabolism. Methods mRNA and protein expression of dopamine receptors D1 and D2 (DRD1 and DRD2) were determined in subcutaneous adipose tissue from subjects without or with T2D and with different body weight, and correlated with markers of obesity, hyperglycemia, and insulin resistance. Glucose uptake and lipolysis were measured in adipocytes ex vivo following short-term exposure to dopamine, DRD1 receptor agonist (SKF81297), or DRD2 receptor agonist (bromocriptine). Results DRD1 and DRD2 gene expression in subcutaneous adipose tissue correlated positively with clinical markers of insulin resistance (e.g. HOMA-IR, insulin, and triglycerides) and central obesity in subjects without T2D. Protein expression of DRD2 in subcutaneous adipose tissue, but not DRD1, is higher in subjects with impaired fasting glucose and T2D and correlated positively with hyperglycemia, HbA1c, and glucose AUC, independent of obesity status. DRD1 and DRD2 proteins were mainly expressed in adipocytes, compared to stromal vascular cells. Dopamine and dopaminergic agonists did not affect adipocyte glucose uptake ex vivo, but DRD1 and DRD2 agonist treatment inhibited isoproterenol-stimulated lipolysis. Conclusion The results suggest that protein expression of DRD2 in subcutaneous adipose tissue is up-regulated with hyperglycemia and T2D. Whether DRD2 protein levels contribute to T2D development or occur as a secondary compensatory mechanism needs further investigation. Additionally, dopamine receptor agonists inhibit adipocyte beta-adrenergic stimulation of lipolysis, which might contribute to the beneficial effects in lipid metabolism as observed in patients taking bromocriptine.


Introduction
Dopamine is a neurotransmitter that binds to specific receptors belonging to the G protein-coupled receptor family, which are categorized into two main families: D1-like (D1 and D5) and D2-like (D2, D3, and D4) [1].These receptors are widely expressed in the central nervous system (CNS) but are also found in the kidney, adrenal glands, gastrointestinal tract, blood vessels, retina, adipose tissue, and heart [2,3].Dopamine plays important roles in the CNS, such as motor control, motivation, reward, cognitive function, maternal, and reproductive behaviors [4], as well as in peripheral tissues, as a modulator of cardiovascular function, catecholamine release, hormone secretion, vascular tone, renal blood flow, and gastrointestinal motility [2].Additionally, dopamine has been shown to play an important role in the regulation of glucose metabolism and energy balance.Studies have shown that dopamine regulates pancreatic endocrine function, including insulin release, in animal models and humans [5].Moreover, a dopamine receptor D2 (DRD2) agonist, bromocriptine, has recently been approved for the treatment of T2D in the USA, with positive effects on glucose tolerance, insulin sensitivity, and circulating lipids [6][7][8].Dopamine is also involved in the modulation of the food reward system, and it has been shown that obese individuals have abnormal brain dopamine activity and reduced striatal DRD2 availability [9,10].This may induce pathological overeating to compensate for the decreased activation of reward circuits modulated by dopamine action [9].Further, it is well known that patients undergoing treatment with antipsychotic drugs, which mainly act as antagonists and/or partial agonists of different dopamine receptors, experience weight gain and related metabolic impairments, such as dyslipidemia, insulin resistance, and the development of T2D [11,12].We have recently shown that the atypical antipsychotic drugs, olanzapine, and aripiprazole, act directly on adipocytes inducing gene expression of the energy balance regulating adipokine leptin [13].In addition, aripiprazole alters adipocyte differentiation and reduces glucose metabolism in differentiated adipocytes.Similarly, we have shown that short-term exposure to second-generation antipsychotics can induce changes in glucose and lipid metabolism in isolated human adipocytes [14].Whether these effects of the antipsychotic drugs are governed via dopaminergic signaling in adipose tissue is not yet known.
The expression of dopamine receptors in adipose tissue has been confirmed in both rodents and humans [15,16], and some dopamine actions have been studied [16][17][18][19].However, the current knowledge of dopaminergic signaling in human adipose tissue in the context of obesity and T2D and its direct implications in adipose tissue metabolism is limited.
In this study, we investigated the expression profiles of dopamine receptors in human adipose tissue of subjects with or without obesity and T2D.Furthermore, we studied the potential involvement of dopamine signaling in the regulation of adipocyte glucose and lipid metabolism.with obesity and T2D undergoing Roux-en-Y Gastric Bypass (RYGB).From all subjects abdominal subcutaneous adipose tissue (SAT) was obtained by needle biopsies from the lower part of the abdomen after local dermal anesthesia with lidocaine (Xylocaine, AstraZeneca).All subjects were recruited at the Uppsala University Hospital.

Subjects
The subjects with T2D were on a stable dose of metformin as their only antidiabetic medication.Sex, age, and BMI-matched patients without T2D [20] and patients undergoing RYGB [21,22] have previously been described in detail.In patients undergoing RYGB SAT obtained by needle biopsies were available at several time points after surgery (at 4, 24, and 104 weeks).
Subjects with type 1 diabetes, endocrine disorders, cancer, or other major diseases, as well as subjects taking medications such as antipsychotics, antidepressants, neuroleptic drugs, or dopaminergic drugs, were excluded from the study.Blood samples were collected after overnight fasting ( > 10 h) for the analysis of HbA1c, plasma glucose and lipids, and serum insulin at the Department of Clinical Chemistry at Uppsala University Hospital or Sahlgrenska University Hospital using standard clinical methods.Anthropometric and clinical characteristics of all subjects in the two cohorts are shown in Table 1.
Adipose tissue samples were snap-frozen in liquid nitrogen and used for mRNA and protein expression analyses.Furthermore, mature adipocytes were isolated from adipose tissue and used for adipocyte size measurements and ex vivo analyses of lipolysis and glucose uptake without and with dopamine and dopamine receptors agonists.Importantly, not all assessments were done for all subjects due to limitations in the amount of adipose tissue available.

Adipocyte glucose uptake and lipolysis, and cell size
Mature adipocytes were isolated from SAT (cohort 1) and used for the assessment of ex vivo lipolysis (n = 16), glucose uptake (n = 46), and adipocyte size measurement (n = 63) as previously reported [20,[23][24][25].Briefly, the tissue was digested in collagenase solution (1.0 mg/mL, from Clostridium histolyticum, Roche) in Hank's medium (Medium 199, Gibco, Life Technologies) supplemented with 5.6 mM glucose, 4% bovine serum albumin (BSA, Sigma), 150 nM adenosine (Sigma), pH 7.4, in a shaking water bath at 37 °C and 105 RPM.Following digestion with collagenase, the tissue was filtered through a nylon mesh, and mature adipocytes were isolated, washed, and suspended in Hank's medium.The cell diameter of 100 consecutive cells was measured by light microscopy, as previously reported [23].Lipolysis was determined by measuring the levels of glycerol in the medium released by adipocytes, and glucose uptake was measured by the adipocyte 14 C glucose uptake into adipocytes, following the incubation without or with insulin (25 and 1000 µU/mL).

Gene expression
SAT (cohorts 1 and 2, n = 168) and OAT (cohort 2, n = 52) were used for total RNA isolation using the RNeasy lipid tissue mini kit (Qiagen).The concentration and purity assessment of total RNA was performed with the Nanodrop (Thermo Scientific).RNA samples were used to synthesize cDNA using a High-Capacity cDNA Reverse Transcriptase kit (Applied Biosystems) according to the manufacturer's guidelines.DNA contamination was monitored by including no reverse transcriptase (NRT) controls in the cDNA synthesis reactions for a sub-set of adipose tissue samples.Expression levels of DRD1 (Hs00265245), DRD2 (Hs00241436), and DRD4 (Hs00609526) were determined using TaqMan gene expression assays (Thermo Fisher), detected using the QuantStudio 3 sequence detection system (Applied Biosystem) and calculated as 2 -deltaCT .The gene expression levels were normalized to the housekeeping gene GUSB (Hs00939627).

Western blot
Total protein lysates were prepared from SAT and OAT (cohorts 1 and 2, n = 27/8 for SAT/OAT), as previously reported [29].Briefly, adipose tissue was homogenized with lysis buffer (25 mM Tris-HCl; 0.5 mM EGTA; 25 mM NaCl; 1% Nonidet P-40; 1 mM Na3VO4; 10 mM NaF (all from Sigma); 100 nM okadaic acid (Alexis Biochemicals), 1X Complete protease inhibitor cocktail (Roche), and pH 7.4), and samples were rocked for 60 min at 4 °C and centrifuged at 12,000 × g for 15 min at 4 °C.The lysate was collected, and the protein concentration was determined using a BCA protein assay kit (Pierce, Thermo Scientific).Protein lysates (10-15 µg) were separated by SDS-PAGE (5-8% gradient, BioRad), transferred to nitrocellulose membranes, and blocked for one hour at room temperature with 0.05% tweenphosphate buffer saline (PBST, Medicago) with 5% BSA.Membranes were incubated overnight in the solution of the primary antibodies: anti-DRD1 (1:1000; Sigma Aldrich D2944) and anti-DRD2 (1:1000; Merck Millipore AB5084P), previously validated [30].Stainfree blot imaging was used to quantify the total protein for each sample and to normalize DRD1 and DRD2 protein levels [31].Membranes were then washed with PBST buffer and incubated with appropriate horseradish peroxidase-conjugated anti-rabbit and anti-rat (Cell Signaling Technologies) secondary antibodies.Protein bands were visualized using enhanced chemiluminescence with a high-resolution field and quantified with ChemiDocTM MP System (BioRad).

Statistical analysis
Descriptive data are presented as mean ± SEM unless stated otherwise.All data were first checked for normality using the Shapiro-Wilk test and by analyzing histograms.Spearman's correlation test was performed between DRD1 mRNA, DRD1, and DRD2 protein expression and clinical markers of obesity, hyperglycemia, and insulin resistance.Kendall's tau-b (τ b ) was used for DRD2 mRNA expression correlation analysis to avoid potential problems of nonnormality, sensitivity to outliers, and ranked expression values [32].Samples without detectable levels of DRD2 mRNA were set to 1/10 of the lowest detection level.Mann-Whitney U or two-sample t-test was used for analyses between 2 independent groups.Protein data were logtransformed prior to analyses.Comparison between more than 2 groups was made using one-way ANOVA.The false discovery rate with the original Benjamini and Hochberg method was used for multiple comparison corrections.All statistical analyses were performed using IBM SPSS Statistics 28 and GraphPad Prism 9.5 software, and the p < 0.05 value was considered statistically significant.

DRD1 and DRD2 gene and protein expression levels in human adipose tissue (SAT vs OAT)
mRNA expression of DRD1 was detected in all samples, whilst DRD2 expression was detected in ~85% of SAT and ~80% of OAT samples.Furthermore, the mRNA expression of DRD1 was significantly higher than DRD2 expression in both SAT and OAT (p < 0.001) (Fig. 1A, B).DRD4 mRNA expression was also measured in human SAT and OAT but was not detected in these tissues.
DRD1 and DRD2 mRNA expression was measured in paired samples of SAT and OAT obtained from subjects without T2D (cohort 2).DRD1 mRNA expression was ~30% lower in OAT compared to SAT (p = 0.05) (Fig. 1C), but the protein levels did not differ between the depots (Fig. 1D).DRD2 mRNA and protein expression were ~40% lower in OAT compared to SAT (p < 0.05) (Fig. 1E, F, respectively).
Additionally, we assessed protein levels of DRD1 and DRD2 in adipocytes and the stromal vascular fraction (SVF) obtained from SAT.To account for different proportions of adipocytes and SVF cells in SAT, we calculated the total protein proportion of adipocytes and SVF in the whole-adipose tissue sample and determined that SVF contributed with less than 1% for both DRD1 and DRD2 protein expression (p < 0.01) (Fig. 1G, H).
DRD1 and DRD2 gene and protein expression in SAT from subjects with and without T2D and obesity Gene expression of DRD1 and DRD2 was measured in SAT from subjects without and with T2D (cohort 1).Subjects without T2D were further subdivided into those with normal glucose tolerance (NGT) or impaired fasting glucose (IFG) using the WHO criteria of IFG with a lower cut-off of 6.1 mmol/L [33].DRD1 mRNA expression in SAT was significantly increased in subjects with T2D compared to subjects without T2D with NGT but not in subjects without T2D with IFG (Fig. 2A).No differences in protein expression were found between the groups (Fig. 2B).For DRD2, the mRNA levels were significantly higher in subjects without T2D with IFG compared to those with NGT but no significant difference was found between subjects with T2D and those with NGT (Fig. 2C).However, DRD2 protein was significantly increased by about 2-fold in subjects with IFG and those with T2D, compared to subjects with NGT (Fig. 2D).
Next, we investigated whether DRD1 and DRD2 gene and protein expression in SAT differed between lean, overweight, and obese subjects without T2D.We found that DRD1 and DRD2 gene expression in SAT was up-regulated in subjects with overweight (BMI: 25-29 kg/m 2 ) or subjects with obesity (BMI: ≥30 kg/m 2 ), compared to lean subjects (Fig. 2E, G).Subjects with obesity had ~2-fold higher protein expression of DRD2 than lean subjects (Fig. 2H), but DRD1 protein levels only showed a tendency to higher levels in subjects with obesity compared to lean subjects (Fig. 2F).

Impact of weight loss on DRD1 and DRD2 expression in SAT from subjects with obesity and T2D
To determine the impact of weight loss, gene and protein expression of DRD1 and DRD2 was also measured in SAT from subjects with obesity and T2D, before (baseline) and at several time points after the RYGB surgery (at 4, 24, and 104 weeks post-RYGB; cohort 1) (Fig. 3).A rapid decrease was observed in the DRD1 gene and protein expression levels 4 weeks post-RYGB (p < 0.05) (Fig. 3A, C), with sustained mRNA levels up to 104 weeks post-surgery (p < 0.01) (Fig. 3A).There was no difference in the DRD2 gene and protein expression levels before and after RYGB (Fig. 3B, D).In addition, these subjects were compared to subjects without T2D (age-and BMI-matched subjects at 104 weeks post-RYGB) that did not undergo weight-loss surgery ("non-obese" controls, Fig. 3).DRD1 gene expression levels at all time points post-RYGB were similar to levels in the BMI-and age-matched "non-obese" control group (Fig. 3A).2).When dividing subjects by T2D status (with and without), similar correlations were observed in subjects without T2D, but in the T2D group, DRD1 gene expression only correlated positively with adipocyte size (p < 0.05).
In subjects without and with T2D taken together, DRD2 gene expression in SAT correlated positively with fasting insulin and HOMA-IR (p < 0.05, both) (Table 3).In subjects without T2D, similar correlations were observed, with the addition of a positive correlation with WHR (p < 0.05) and fasting glucose (p = 0.001).In subjects with T2D, DRD2 expression tended to correlate positively with ex vivo insulin-stimulated glucose uptake (p = 0.051).

Correlation of DRD1 and DRD2 protein expression with hyperglycemia and obesity
Since protein levels of DRD1 and DRD2 generally did not follow mRNA expression patterns, we performed correlation analyses between DRD1 and DRD2 protein expression and obesity and hyperglycemia in subjects without T2D and with NGT or IFG, and T2D (cohort 1), respectively (Fig. 4).When considering both subjects without and with T2D, DRD2 protein expression correlated positively with HbA1c (p = 0.029) and AUC glucose during OGTT (p = 0.034), independently of obesity status (Fig. 4E, F, respectively, and Table 4).DRD2 protein expression was not significantly associated with the insulin resistance marker HOMA-IR.No significant correlations were observed between DRD1 protein expression and the clinical characteristics of the subjects (Fig. 4A-C).

Effects of dopamine and dopamine receptor agonists on adipocyte glucose uptake and lipolysis
Dopamine at physiological (1 and 50 nM) concentrations did not alter adipocyte basal or insulin-stimulated glucose uptake ex vivo, while a supra-physiological concentration (100 nM) caused a minor reduction in insulin-stimulated glucose uptake by ~10% (p < 0.05) (Fig. 5A).Furthermore, dopamine did not affect either basal or isoproterenolstimulated lipolysis in adipocytes, ex vivo (Fig. 5B).

Discussion
Taken together, the results in this study suggest that DRD2 protein expression is increased in subjects with obesity, impaired fasting glucose (IFG), and type 2 diabetes (T2D), and positively correlated with hyperglycemia.Additionally, DRD1 protein expression is increased in subjects with overweight/obesity, but not T2D.Further, adipocyte isoproterenol-stimulated lipolysis was reduced following treatment with DRD1 and DRD2 agonists.
Adipose tissue is an important endocrine organ involved in the regulation of whole-body energy homeostasis and has a crucial role in linking obesity to increased risk of insulin resistance, dyslipidemia, and T2D [34].Literature shows that dopamine affects whole-body energy balance by regulating eating-related behaviors in the CNS and insulin secretion from the pancreas [35,36].Despite growing evidence for peripheral dopamine production and action, and expression of dopamine receptors in peripheral tissues, including adipose tissue, most studies up until now have focused on dopamine functions in the CNS.
In this study, we confirm that human adipose tissue expresses DRD1 and DRD2, with a significantly higher expression of DRD1 compared to DRD2, in both SAT and OAT.Previous reports have also shown the expression of DRD4 in human cell lines and visceral adipose tissue [15,16], but we have not detected the expression of DRD4 in SAT or OAT in this study.Apart from cell-and depot-specific differences in DRD4 expression, discrepant findings could also be due to the use of methods with different detection sensitivity (TaqMan vs. high throughput chip platform).
The gene expression of DRD1 was lower in SAT compared to OAT, but this was not found for the protein expression.As far as we know, a direct comparison of the DRD1 expression between SAT and OAT has not previously been performed.A previous publication [37] demonstrated that DRD2 gene expression was increased in visceral (omental) compared to subcutaneous adipocytes.In contrast, we show that the DRD2 gene and protein expression was lower in OAT compared to SAT.These conflicting findings could be due to differences in the subjects' characteristics and populations studied in the different studies.To account for different proportions of the receptors on adipocytes and SVF cells in SAT, we determined the relative protein levels for these fractions, but DRD1 and DRD2 protein expression were mainly found in adipocytes when compared to SVF and this is in accordance with previously published data [37].We observed a significant increase in DRD2 receptor protein levels even prior to the development of T2D, in subjects with IFG and obesity.Accordingly, DRD2 protein expression positively correlated with hyperglycemia markers.This led us to hypothesize that either the DRD2 receptors on adipocytes could have implications for the development of insulin resistance and T2D, or their expression could be changed as a compensatory mechanism counterbalancing for example hyperglycemia or altered nutrient availability.Future studies should investigate how the exposure of adipose tissue to different glucose concentrations affects the expression of DRD2.Adipocyte exposure to varying glucose concentrations and measuring levels of DRD2 could provide a response regarding the direction of the changes.Further, longitudinal studies investigating the impact of T2D development on DRD2 levels could be useful to overcome the limitation of our cross-sectional study and produce a clearer picture of the role of DRDs´in adipose tissue functions.Previously, it has been reported that the DRD2 gene expression does not change in OAT of subjects with obesity and T2D, compared to subjects with obesity but without T2D [16].The apparent discrepancy could be due to the type of adipose tissue studied, while we studied SAT, the previous group investigated OAT, and also due to the differences in the studied populations.
DRD1 gene expression was increased in subjects with obesity with a tendency to be additionally increased with T2D and positively correlated with adiposity markers and insulin resistance.However, the DRD1 protein levels did not follow the gene expression data, when comparing subjects without and with obesity or T2D.Additionally, no correlations were found between DRD1 protein expression and markers of insulin resistance and obesity.Thus, the results of the association study should be considered with reservation.The significantly discordant changes between the protein and mRNA levels in our study suggest that posttranscriptional or post-translational regulatory mechanisms regulate the protein expression of DRD1 [38].This highlights the necessity to assess both mRNA and protein levels of dopamine receptors in future experimental designs.Interestingly, DRD1 gene and protein expression was markedly decreased shortly after RYGB surgery, and mRNA levels were sustained during follow-up for up to 104 weeks.RYGB is an effective obesity treatment, and patients experience rapid changes in weight and improvements in glycemic control and insulin sensitivity [22].There is also evidence that RYGB can modulate dopamine receptors and dopamine action levels in the brain and periphery (e.g.pancreas) independently of weight loss [39][40][41].Whether observed changes in adipose tissue DRD1 expression are governed by weight loss or other mechanisms, potentially through communication with other organs, requires further investigation.
It has previously been shown that bromocriptine, a DRD2 receptor agonist, has positive effects on glucose Fig. 5 Effects of dopamine and dopamine receptor agonists on subcutaneous adipocyte metabolism.Dopamine effects on (A) basal and insulinstimulated adipocyte glucose uptake and on (B) basal and isoproterenol-stimulated adipocyte lipolysis.(n = 7 and 3 without T2D from cohort 1, respectively).SKF81297 (D1 receptor agonist) and bromocriptine (D2 receptor agonist) effects on (C) basal and insulin-stimulated adipocyte glucose uptake, and (D) basal and isoproterenol-stimulated adipocyte lipolysis (n = 3 and 4 without T2D from cohort 1, respectively).Data are shown as mean ± SEM. *p < 0.05, **p < 0.01.ISO isoproterenol tolerance, insulin sensitivity, and cardiovascular risk in subjects with and without T2D [6,42,43] and is approved as a treatment for T2D in the USA by the FDA [44].The glucose metabolic effects of bromocriptine, have mainly been attributed to its actions in the CNS [8].However, with the known expression of dopamine receptors outside the CNS, the potential direct effects of dopamine on adipocyte metabolism are possible.Our functional assessment demonstrated that dopamine, SKF38393 (DRD1 agonist), and bromocriptine (DRD2 agonist) with concentrations up to 100 nM do not directly affect subcutaneous adipocyte glucose uptake ex vivo.A recent study showed that high concentrations (10 µM) of dopamine or bromocriptine can act to enhance insulin signaling in rat mesenchymal adipose tissue [45].The apparent discrepant findings could be due to differences in species, adipocyte origin, or the higher concentrations used in the abovementioned study.
Additionally, our results show that acute ex vivo treatment of subcutaneous adipocytes with dopamine does not directly affect lipolysis, however, treatment with DRD1 and DRD2 agonists inhibited isoproterenol-stimulated lipolysis.These results are consistent with previous studies showing that bromocriptine and SKF81297 treatment inhibits lipolysis in rodents [46][47][48].Moreover, in subjects with and without T2D, bromocriptine treatment lowers triglycerides, FFAs, and cardiometabolic risk [8,49,50].Such effects to inhibit lipolysis in adipocytes are likely to lead to improvements in circulating lipids with a protective role in the liver and heart [8,51].It should also be noted that previous studies have shown contradictory results regarding the involvement of dopaminergic signaling in lipid metabolism.It has been shown that 24-hour incubation of adipocytes from a murine cell line with a specific DRD1 receptor agonist stimulates lipolysis [17].In another study, bromocriptine treatment in patients induces an increase in circulating FFA levels [49].Taken together, these data suggest that the effects of dopaminergic signaling might be dependent on different factors, such as duration of treatment, genomic effects [37], communication with other organs, such as the brain or gut, and time-of-day dependent effects [52].
This study of course has some limitations.The correlations are hypothesis-generating and explorative, and they do not assume causality.Thus, functional assessment of dopaminergic signaling on human adipose tissue glucose and lipid metabolism was performed, but in a limited number of subjects and only in SAT.Further, the number of samples used for mRNA analyses was much higher than for protein, and it would have been preferable to analyze protein levels in the same number of samples as we did mRNA expression.Dopamine levels in human adipose tissue are not known, therefore the dopamine concentrations used reflect circulating dopamine levels [26,27].Also, in previous publications, dopamine shows a non-linear responsiveness in adipocytes [15] hence, the dopamine concentrations used in this adipose tissue ex vivo approach do not necessarily reflect the in vivo setting.Thus, additional in vivo functional assessment would be preferred, for example in subjects exposed to compounds targeting dopamine receptors.
In summary, DRD2 mRNA and protein expression in SAT was associated with hyperglycemia independently of obesity status and increased in subjects with impaired fasting glucose and T2D.DRD1 gene expression was increased in subjects with overweight/obesity, but protein expression did not follow gene expression data.Dopamine (1, 50, and 100 nM) did not affect subcutaneous adipocyte glucose uptake and lipolysis ex vivo, but DRD1 and DRD2 agonists inhibited isoproterenol-stimulated lipolysis.
In conclusion, these results suggest that the protein expression of DRD2 in SAT is up-regulated with hyperglycemia and T2D.Whether these changes have direct consequences for the development of T2D, or result from a metabolic adaptation needs further investigation.Additionally, dopamine receptor agonists attenuate adipocyte betaadrenergic stimulation of lipolysis, which may potentially contribute to beneficial effects in lipid metabolism observed in patients taking bromocriptine.

Fig. 1 Fig. 2
Fig.1Dopamine receptors expression in human adipose tissue.A DRD1 and DRD2 mRNA expression in human SAT.n = 87, subjects without T2D, cohort 1. B DRD1 and DRD2 mRNA expression in human OAT.n = 52, cohort 2. C, E DRD1 and DRD2 mRNA expression in paired SAT and OAT.n = 52, cohort 2. D, F DRD1 and DRD2 protein expression in paired SAT and OAT.n = 7, cohort 2. G, H DRD1 and DRD2 total protein expression in mature adipocytes and SVF in SAT.n = 3, subjects without T2D, cohort 1.Western blot data are shown as relative to total protein and a representative immunoblot of total protein levels is provided in online resource 1.Data are shown as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001.SAT subcutaneous adipose tissue, OAT omental adipose tissue, SVF stromal vascular fraction

Fig. 3
Fig. 3 Impact of weight loss with bariatric surgery on DRD1 and DRD2 expression in SAT from subjects with obesity and T2D.A, B DRD1 and DRD2 mRNA expression in subjects with obesity and T2D at baseline and 4, 24, and 104 weeks post-RYGB, and in controls without obesity and T2D.n = 8-12 from cohort 1. C, D DRD1 and

Fig. 4
Fig. 4 DRD1 and DRD2 protein expression correlation with markers of obesity and hyperglycemia.A-C DRD1 and D-F DRD2 protein expression association with BMI, HbA1c, and AUC glucose during an OGTT.Dopamine receptors expression in SAT from subjects with and